Logo image of PMCB

PHARMACYTE BIOTECH INC (PMCB) Stock Fundamental Analysis

NASDAQ:PMCB - Nasdaq - US71715X2036 - Common Stock - Currency: USD

1.11  -0.03 (-2.63%)

Fundamental Rating

3

PMCB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. PMCB has a great financial health rating, but its profitability evaluates not so good. PMCB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PMCB had positive earnings in the past year.
In the past year PMCB has reported a negative cash flow from operations.
In the past 5 years PMCB always reported negative net income.
PMCB had a negative operating cash flow in each of the past 5 years.
PMCB Yearly Net Income VS EBIT VS OCF VS FCFPMCB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With an excellent Return On Assets value of 19.70%, PMCB belongs to the best of the industry, outperforming 97.12% of the companies in the same industry.
Looking at the Return On Equity, with a value of 21.45%, PMCB belongs to the top of the industry, outperforming 96.58% of the companies in the same industry.
Industry RankSector Rank
ROA 19.7%
ROE 21.45%
ROIC N/A
ROA(3y)-13.12%
ROA(5y)-29.88%
ROE(3y)-18.09%
ROE(5y)-36.53%
ROIC(3y)N/A
ROIC(5y)N/A
PMCB Yearly ROA, ROE, ROICPMCB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PMCB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMCB Yearly Profit, Operating, Gross MarginsPMCB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for PMCB has been reduced compared to 1 year ago.
Compared to 5 years ago, PMCB has more shares outstanding
There is no outstanding debt for PMCB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PMCB Yearly Shares OutstandingPMCB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
PMCB Yearly Total Debt VS Total AssetsPMCB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

PMCB has an Altman-Z score of -1.72. This is a bad value and indicates that PMCB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.72, PMCB is in line with its industry, outperforming 54.41% of the companies in the same industry.
There is no outstanding debt for PMCB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.72
ROIC/WACCN/A
WACCN/A
PMCB Yearly LT Debt VS Equity VS FCFPMCB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 14.20 indicates that PMCB has no problem at all paying its short term obligations.
PMCB's Current ratio of 14.20 is amongst the best of the industry. PMCB outperforms 86.13% of its industry peers.
A Quick Ratio of 14.20 indicates that PMCB has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 14.20, PMCB belongs to the best of the industry, outperforming 86.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.2
Quick Ratio 14.2
PMCB Yearly Current Assets VS Current LiabilitesPMCB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

PMCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 170.22%, which is quite impressive.
EPS 1Y (TTM)170.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMCB Yearly EPS VS EstimatesPMCB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2022 -10 -20 -30

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 1.01 indicates a rather cheap valuation of PMCB.
Based on the Price/Earnings ratio, PMCB is valued cheaper than 99.64% of the companies in the same industry.
When comparing the Price/Earnings ratio of PMCB to the average of the S&P500 Index (27.45), we can say PMCB is valued rather cheaply.
Industry RankSector Rank
PE 1.01
Fwd PE N/A
PMCB Price Earnings VS Forward Price EarningsPMCB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMCB Per share dataPMCB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PMCB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMACYTE BIOTECH INC

NASDAQ:PMCB (7/3/2025, 8:00:46 PM)

1.11

-0.03 (-2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17 2025-03-17/amc
Earnings (Next)08-11 2025-08-11
Inst Owners8.36%
Inst Owner Change-5.42%
Ins Owners2.7%
Ins Owner Change0%
Market Cap7.61M
Analysts43.33
Price TargetN/A
Short Float %0.35%
Short Ratio2.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1.01
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB 0.2
EV/EBITDA N/A
EPS(TTM)1.1
EY99.1%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS5.87
TBVpS5.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 19.7%
ROE 21.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.12%
ROA(5y)-29.88%
ROE(3y)-18.09%
ROE(5y)-36.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.2
Quick Ratio 14.2
Altman-Z -1.72
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.68%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.65%
OCF growth 3YN/A
OCF growth 5YN/A